The Korean journal of internal medicine

  • 제22권2호
  • /
  • Pages.109-112
  • /
  • 2007
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report

  • Lee, Sehe-Dong (Department of Internal Medicine, Seoul Veterans Hospital) ;
  • Kim, Hye-Jeon (Department of Internal Medicine, Seoul Veterans Hospital) ;
  • Hwang, Seung-Jae (Department of Internal Medicine, Seoul Veterans Hospital) ;
  • Kim, Yoon-Jung (Department of Pathology, Seoul Veterans Hospital) ;
  • Nam, Seung-Hyun (Department of Internal Medicine, Seoul Veterans Hospital) ;
  • Kim, Bong-Seog (Department of Internal Medicine, Seoul Veterans Hospital)
  • 발행 : 20070600
⟨ 이전 논문 다음 논문 ⟩

초록

Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function. We report a case of HFS, with scleroderma-like changes, apparently induced by capecitabine. In our case, capecitabine, given in the recommended dosage was observed to lead to hyperpigmentation of the palms and soles, followed by a distinct keratoderma-like thickening unfamiliar to usual cases of HFS. This case may provide important clues for revising the definition of HFS, and allow the formation of effective preventive strategies for this side effect of chemotherapy.

키워드

참고문헌

  1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998 https://doi.org/10.1016/S0959-8049(98)00058-6
  2. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16:1795-1802, 1998 https://doi.org/10.1200/JCO.1998.16.5.1795
  3. SchullerJ, CassidyJ, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000 https://doi.org/10.1007/s002800050043
  4. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001 https://doi.org/10.1200/JCO.2001.19.8.2282
  5. van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106, 2001 https://doi.org/10.1200/JCO.2001.19.21.4097
  6. Cassidy J, Twelves C, van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002 https://doi.org/10.1093/annonc/mdf089
  7. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999 https://doi.org/10.1200/JCO.1999.17.2.485
  8. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 20:3-10, 2002 https://doi.org/10.1081/CNV-120000360
  9. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:798-799, 1984 https://doi.org/10.7326/0003-4819-101-6-798
  10. Meta-Analysis Group in Cancer. Toxicity of Fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998 https://doi.org/10.1200/JCO.1998.16.11.3537
  11. Capecitabine (Xeloda). In: Physicians' desk reference. 55th ed. p. 2606-2809, Montvale, Medical Economics, 2001
  12. Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 73:101-106, 2004
  13. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457-461, 1991 https://doi.org/10.1016/0190-9622(91)70073-B
  14. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173, 1995 https://doi.org/10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H